

80. (New) The polynucleotide of Claim 78, wherein said polynucleotide is at least 20 contiguous nucleotides of the nucleotide sequence from residue number 155 to 973 of SEQ ID NO:64.

B1
(cont'd)
81. (New) The polynucleotide of Claim 78, wherein said polynucleotide is at least 23 contiguous nucleotides of the nucleotide sequence from residue number 155 to 973 of SEQ ID NO:64.

82. (New) The polynucleotide of Claim 78, wherein said polynucleotide is at least 30 contiguous nucleotides of the nucleotide sequence from residue number 155 to 973 of SEQ ID NO:64.

83. (New) The polynucleotide of Claim 78, 79, 80, 81, or 82 which further comprises a label.--

REMARKS

Claims 53-83 are currently pending. Claims 1-52 have been canceled without prejudice, and Applicant reserves the right to pursue the subject matter of these claims in additional applications.

New Claims 52-83 have been added to more particularly point out and distinctly claim that which Applicant regards as the invention. In general, new Claims 52-83 correspond to canceled claims 1-19, as originally filed, which were directed to polynucleotides, host cells, vectors, and methods of making polypeptides using such polynucleotides. The claims are completely supported in the specification as filed and no new matter has been introduced.

More specifically, support for the specified amino acid and nucleotide residue numbers of Claims 54, 56, 57, and 78-82 can be found, for example, in the specification at page 163, lines 17-33, and Figures 9A-B, 11, and 8A-B.

Support for the highly stringent hybridization conditions recited in Claims 61, 63, and 65 can be found at page 43, lines 20-26 of the specification, for example.

Support for Claims 62, 64, and 66, with respect to down regulation in endothelial cells under shear stress and inhibition of TGF- β signalling can be found, for example, at Sections 9 16.2 of the specification.

Support for Claim 67, with respect to human polynucleotides, can be found, for example, at page 162, line 10 of the specification.

Support for Claims 78-81, regarding the respective specified lengths of polynucleotides can be found, for example, at page 44, lines 11-13 of the specification.

Support for Claim 82, regarding the specified length of polynucleotide can be found, for example, at page 104, line 33 of the specification.

Applicant respectfully requests that the above-made amendments and remarks be entered and made of record in the file history of the instant application.

Respectfully submitted,

Date: June 7, 1999

 41,119
Jonathan L. Klein (Reg. No.)

For: Laura A. Coruzzi, Reg. No. 30,742

PENNIE & EDMONDS
1155 Avenue of the Americas
New York, N.Y. 10036
Phone: (212) 790-9090
Local: (202) 496-4400